SS-31 (Elamipretide) vs KPV

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

SS-31 (Elamipretide)

SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.

Full details →

KPV

KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the tanning or other melanocortin effects.

Full details →

Side-by-Side Comparison

AspectSS-31 (Elamipretide)KPV
MechanismConcentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency.Inhibits NF-κB activation and reduces inflammatory cytokine production. Enters cells and directly modulates inflammatory signaling without requiring melanocortin receptors.
Typical DosageClinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily.Oral/sublingual: 200-500mcg 1-3 times daily. Topical formulations for localized inflammation. Also used in enemas for gut inflammation.
AdministrationCan be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions.Can be taken orally, sublingually, or as suppositories/enemas for gut inflammation. Topical use for skin conditions. Stable orally unlike most peptides.
Side EffectsGenerally well-tolerated. Clinical trials reported injection site reactions and occasional headache.Generally very well-tolerated. Minimal systemic effects due to targeted anti-inflammatory action.
Best For

What They Have in Common

Both SS-31 (Elamipretide) and KPV are commonly used for:

Key Differences

Unique to SS-31 (Elamipretide):

Unique to KPV:

Ready to Learn More?